|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TPSAB1 |
Gene summary for TPSAB1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TPSAB1 | Gene ID | 7177 |
| Gene name | tryptase alpha/beta 1 | |
| Gene Alias | TPS1 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | P20231 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7177 | TPSAB1 | CA_HPV_1 | Human | Cervix | CC | 6.15e-24 | -1.03e+00 | 0.0264 |
| 7177 | TPSAB1 | CA_HPV_3 | Human | Cervix | CC | 5.12e-06 | -5.87e-01 | 0.0414 |
| 7177 | TPSAB1 | N_HPV_2 | Human | Cervix | N_HPV | 9.13e-10 | -8.31e-01 | -0.0131 |
| 7177 | TPSAB1 | CCI_1 | Human | Cervix | CC | 2.58e-06 | -1.28e+00 | 0.528 |
| 7177 | TPSAB1 | CCI_2 | Human | Cervix | CC | 1.08e-05 | -1.28e+00 | 0.5249 |
| 7177 | TPSAB1 | CCI_3 | Human | Cervix | CC | 8.25e-09 | -1.28e+00 | 0.516 |
| 7177 | TPSAB1 | CCII_1 | Human | Cervix | CC | 1.23e-12 | -1.28e+00 | 0.3249 |
| 7177 | TPSAB1 | Tumor | Human | Cervix | CC | 2.01e-33 | -1.28e+00 | 0.1241 |
| 7177 | TPSAB1 | sample1 | Human | Cervix | CC | 2.19e-10 | -1.28e+00 | 0.0959 |
| 7177 | TPSAB1 | sample3 | Human | Cervix | CC | 2.08e-31 | -1.28e+00 | 0.1387 |
| 7177 | TPSAB1 | H2 | Human | Cervix | HSIL_HPV | 2.24e-34 | -1.22e+00 | 0.0632 |
| 7177 | TPSAB1 | L1 | Human | Cervix | CC | 5.78e-14 | -1.28e+00 | 0.0802 |
| 7177 | TPSAB1 | T1 | Human | Cervix | CC | 1.11e-23 | -1.28e+00 | 0.0918 |
| 7177 | TPSAB1 | T2 | Human | Cervix | CC | 2.57e-05 | -1.28e+00 | 0.0709 |
| 7177 | TPSAB1 | T3 | Human | Cervix | CC | 3.29e-32 | -1.28e+00 | 0.1389 |
| 7177 | TPSAB1 | C21 | Human | Oral cavity | OSCC | 2.38e-02 | -9.52e-02 | 0.2678 |
| 7177 | TPSAB1 | EOLP-1 | Human | Oral cavity | EOLP | 4.22e-28 | 1.13e+00 | -0.0202 |
| 7177 | TPSAB1 | EOLP-2 | Human | Oral cavity | EOLP | 2.55e-45 | 1.44e+00 | -0.0203 |
| 7177 | TPSAB1 | NEOLP-1 | Human | Oral cavity | NEOLP | 2.05e-16 | 8.00e-01 | -0.0194 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002241110 | Cervix | CC | cellular component disassembly | 83/2311 | 443/18723 | 6.04e-05 | 8.68e-04 | 83 |
| GO:0030198 | Cervix | CC | extracellular matrix organization | 52/2311 | 301/18723 | 7.43e-03 | 3.98e-02 | 52 |
| GO:0043062 | Cervix | CC | extracellular structure organization | 52/2311 | 302/18723 | 7.92e-03 | 4.17e-02 | 52 |
| GO:0022617 | Cervix | CC | extracellular matrix disassembly | 15/2311 | 63/18723 | 8.52e-03 | 4.40e-02 | 15 |
| GO:0045229 | Cervix | CC | external encapsulating structure organization | 52/2311 | 304/18723 | 9.00e-03 | 4.57e-02 | 52 |
| GO:002241114 | Cervix | N_HPV | cellular component disassembly | 23/534 | 443/18723 | 4.41e-03 | 3.33e-02 | 23 |
| GO:002241119 | Oral cavity | OSCC | cellular component disassembly | 283/7305 | 443/18723 | 9.57e-27 | 3.37e-24 | 283 |
| GO:00301983 | Oral cavity | OSCC | extracellular matrix organization | 146/7305 | 301/18723 | 4.67e-04 | 2.77e-03 | 146 |
| GO:00452293 | Oral cavity | OSCC | external encapsulating structure organization | 147/7305 | 304/18723 | 5.30e-04 | 3.08e-03 | 147 |
| GO:00430623 | Oral cavity | OSCC | extracellular structure organization | 146/7305 | 302/18723 | 5.59e-04 | 3.23e-03 | 146 |
| GO:00226171 | Oral cavity | OSCC | extracellular matrix disassembly | 37/7305 | 63/18723 | 1.18e-03 | 5.99e-03 | 37 |
| GO:002241121 | Oral cavity | EOLP | cellular component disassembly | 94/2218 | 443/18723 | 1.00e-08 | 4.89e-07 | 94 |
| GO:003019811 | Oral cavity | EOLP | extracellular matrix organization | 52/2218 | 301/18723 | 3.29e-03 | 1.90e-02 | 52 |
| GO:004306211 | Oral cavity | EOLP | extracellular structure organization | 52/2218 | 302/18723 | 3.52e-03 | 2.01e-02 | 52 |
| GO:004522911 | Oral cavity | EOLP | external encapsulating structure organization | 52/2218 | 304/18723 | 4.04e-03 | 2.23e-02 | 52 |
| GO:002241131 | Oral cavity | NEOLP | cellular component disassembly | 87/2005 | 443/18723 | 1.39e-08 | 6.46e-07 | 87 |
| GO:00301982 | Oral cavity | NEOLP | extracellular matrix organization | 64/2005 | 301/18723 | 5.66e-08 | 2.24e-06 | 64 |
| GO:00430622 | Oral cavity | NEOLP | extracellular structure organization | 64/2005 | 302/18723 | 6.44e-08 | 2.50e-06 | 64 |
| GO:00452292 | Oral cavity | NEOLP | external encapsulating structure organization | 64/2005 | 304/18723 | 8.33e-08 | 3.17e-06 | 64 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0516414 | Cervix | CC | Influenza A | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
| hsa0516415 | Cervix | CC | Influenza A | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
| hsa0516422 | Cervix | HSIL_HPV | Influenza A | 23/459 | 171/8465 | 4.65e-05 | 6.48e-04 | 5.24e-04 | 23 |
| hsa0516432 | Cervix | HSIL_HPV | Influenza A | 23/459 | 171/8465 | 4.65e-05 | 6.48e-04 | 5.24e-04 | 23 |
| hsa0516441 | Cervix | N_HPV | Influenza A | 16/349 | 171/8465 | 1.81e-03 | 1.12e-02 | 8.75e-03 | 16 |
| hsa0516451 | Cervix | N_HPV | Influenza A | 16/349 | 171/8465 | 1.81e-03 | 1.12e-02 | 8.75e-03 | 16 |
| hsa0516418 | Oral cavity | OSCC | Influenza A | 116/3704 | 171/8465 | 1.23e-10 | 1.78e-09 | 9.08e-10 | 116 |
| hsa0516419 | Oral cavity | OSCC | Influenza A | 116/3704 | 171/8465 | 1.23e-10 | 1.78e-09 | 9.08e-10 | 116 |
| hsa0516442 | Oral cavity | EOLP | Influenza A | 58/1218 | 171/8465 | 7.01e-11 | 3.23e-09 | 1.91e-09 | 58 |
| hsa0516452 | Oral cavity | EOLP | Influenza A | 58/1218 | 171/8465 | 7.01e-11 | 3.23e-09 | 1.91e-09 | 58 |
| hsa0516461 | Oral cavity | NEOLP | Influenza A | 43/1112 | 171/8465 | 1.38e-05 | 1.22e-04 | 7.68e-05 | 43 |
| hsa0516471 | Oral cavity | NEOLP | Influenza A | 43/1112 | 171/8465 | 1.38e-05 | 1.22e-04 | 7.68e-05 | 43 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TPSAB1 | SNV | Missense_Mutation | novel | c.317N>T | p.Arg106Met | p.R106M | Q15661 | protein_coding | deleterious(0) | probably_damaging(0.924) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TPSAB1 | SNV | Missense_Mutation | novel | c.772A>G | p.Thr258Ala | p.T258A | Q15661 | protein_coding | tolerated(0.59) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TPSAB1 | SNV | Missense_Mutation | rs757030119 | c.736G>A | p.Glu246Lys | p.E246K | Q15661 | protein_coding | tolerated(0.6) | benign(0.037) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| TPSAB1 | SNV | Missense_Mutation | rs757030119 | c.736N>A | p.Glu246Lys | p.E246K | Q15661 | protein_coding | tolerated(0.6) | benign(0.037) | TCGA-FU-A40J-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
| TPSAB1 | SNV | Missense_Mutation | novel | c.85N>A | p.Val29Met | p.V29M | Q15661 | protein_coding | deleterious(0.05) | benign(0.332) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TPSAB1 | SNV | Missense_Mutation | novel | c.794N>C | p.Asp265Ala | p.D265A | Q15661 | protein_coding | tolerated(0.07) | possibly_damaging(0.863) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TPSAB1 | SNV | Missense_Mutation | novel | c.674N>A | p.Gly225Glu | p.G225E | Q15661 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A5-A7WJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TPSAB1 | SNV | Missense_Mutation | novel | c.109N>C | p.Ala37Pro | p.A37P | Q15661 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EY-A1GK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TPSAB1 | SNV | Missense_Mutation | c.260N>A | p.Arg87Lys | p.R87K | Q15661 | protein_coding | tolerated(0.1) | benign(0.138) | TCGA-86-A4D0-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | etoposide | CR | |
| TPSAB1 | SNV | Missense_Mutation | c.64C>A | p.Pro22Thr | p.P22T | Q15661 | protein_coding | deleterious(0.05) | possibly_damaging(0.798) | TCGA-86-A4JF-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 7177 | TPSAB1 | PROTEASE, DRUGGABLE GENOME, ENZYME | inhibitor | 318164852 | CHEMBL256892 | |
| 7177 | TPSAB1 | PROTEASE, DRUGGABLE GENOME, ENZYME | Lactoferrin | |||
| 7177 | TPSAB1 | PROTEASE, DRUGGABLE GENOME, ENZYME | inhibitor | 223366193 | GABEXATE | |
| 7177 | TPSAB1 | PROTEASE, DRUGGABLE GENOME, ENZYME | Pentamidine | PENTAMIDINE | ||
| 7177 | TPSAB1 | PROTEASE, DRUGGABLE GENOME, ENZYME | THROMBIN | THROMBIN | 9020112 | |
| 7177 | TPSAB1 | PROTEASE, DRUGGABLE GENOME, ENZYME | GM-CSF | REGRAMOSTIM | 9130550 | |
| 7177 | TPSAB1 | PROTEASE, DRUGGABLE GENOME, ENZYME | inhibitor | 178101079 | NAFAMOSTAT |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |